Published Dec 23, 2021

Labcorp Strengthens Oncology Leadership Position with the Addition of Personal Genome Diagnostics, a Provider of Comprehensive Liquid Biopsy and Tissue-Based Genomic Products and Services

Broader Access to Innovative Diagnostics Improves Patient Outcomes and Accelerates Clinical Trials

BURLINGTON, N.C., Dec. 23, 2021 — Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.

Click here to read the full press release from the Labcorp newsroom.